Matches in Wikidata for { <http://www.wikidata.org/entity/Q37483253> ?p ?o ?g. }
- Q37483253 description "article científic" @default.
- Q37483253 description "article scientifique" @default.
- Q37483253 description "articolo scientifico" @default.
- Q37483253 description "artigo científico" @default.
- Q37483253 description "artículu científicu espublizáu en 2011" @default.
- Q37483253 description "bilimsel makale" @default.
- Q37483253 description "scientific article published on 17 October 2011" @default.
- Q37483253 description "vedecký článok" @default.
- Q37483253 description "vetenskaplig artikel" @default.
- Q37483253 description "videnskabelig artikel" @default.
- Q37483253 description "vědecký článek" @default.
- Q37483253 description "wetenschappelijk artikel" @default.
- Q37483253 description "wissenschaftlicher Artikel" @default.
- Q37483253 description "наукова стаття, опублікована в жовтні 2011" @default.
- Q37483253 description "научни чланак" @default.
- Q37483253 description "مقالة علمية نشرت في 17 أكتوبر 2011" @default.
- Q37483253 name "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 name "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 name "A phase 1 study of weekly everolimus" @default.
- Q37483253 type Item @default.
- Q37483253 label "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 label "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 label "A phase 1 study of weekly everolimus" @default.
- Q37483253 prefLabel "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 prefLabel "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 prefLabel "A phase 1 study of weekly everolimus" @default.
- Q37483253 P1433 Q37483253-3EC800A9-595F-48D7-ADD0-D7D1B83DA89E @default.
- Q37483253 P1476 Q37483253-1D1B7BC6-F83C-4E62-AC91-C43F5CE6B3AD @default.
- Q37483253 P2093 Q37483253-23456E11-BA0A-422E-B954-4EBA8C9F93F5 @default.
- Q37483253 P2093 Q37483253-3EC62757-CF7D-4294-91F5-1B5F9D07C65B @default.
- Q37483253 P2093 Q37483253-436D6366-799E-4D6A-8B77-3233711158BF @default.
- Q37483253 P2093 Q37483253-7A1FA131-C941-4866-B6F2-FE9616B28F80 @default.
- Q37483253 P2093 Q37483253-90630728-294E-4DAB-8633-26A4AF932CAB @default.
- Q37483253 P2093 Q37483253-9B7869E3-98DF-4059-9ED9-BD6E2609434E @default.
- Q37483253 P2093 Q37483253-C72BBC00-F91E-412C-B62C-FAF229D77570 @default.
- Q37483253 P2093 Q37483253-DFD9F2EF-45E8-4987-BD86-AA8FFF4644A7 @default.
- Q37483253 P2860 Q37483253-0ED41663-EA83-40D5-B222-BFFD0ADC6382 @default.
- Q37483253 P2860 Q37483253-198EF06D-4EE3-41E6-B788-524518B145D5 @default.
- Q37483253 P2860 Q37483253-239B3C8E-3B7A-400D-AD91-794B22EA2FD5 @default.
- Q37483253 P2860 Q37483253-2B81335C-4662-4876-8657-27608422C8B2 @default.
- Q37483253 P2860 Q37483253-32C62744-27E6-4E55-BF57-D3A21519B286 @default.
- Q37483253 P2860 Q37483253-3431CA0D-2050-4197-BD82-D9F006497FA7 @default.
- Q37483253 P2860 Q37483253-3A76CE5E-D6DF-4712-83EE-6512588A454B @default.
- Q37483253 P2860 Q37483253-43358211-D0C0-4664-B89B-30DD5811CCD5 @default.
- Q37483253 P2860 Q37483253-440012D0-AB5F-405F-B47C-5FD7B3372920 @default.
- Q37483253 P2860 Q37483253-4417600C-A0D9-4B27-949D-BC017767F17E @default.
- Q37483253 P2860 Q37483253-4447F7A6-0CF2-4C51-86D8-CD8479CF72C5 @default.
- Q37483253 P2860 Q37483253-5CA43291-8BDB-4498-A473-F1FE570B9BCE @default.
- Q37483253 P2860 Q37483253-60AD3238-1DFF-43A9-9220-70F880C508ED @default.
- Q37483253 P2860 Q37483253-8AE812DF-C8A7-465C-8C49-25F585965ED7 @default.
- Q37483253 P2860 Q37483253-8DEDDA2C-09CF-4FBA-98BD-1EEEEEB7F106 @default.
- Q37483253 P2860 Q37483253-A07715FC-B089-4CCA-AD59-9BF5631A0A66 @default.
- Q37483253 P2860 Q37483253-A1D8321C-D646-4778-8B6A-0BF8B2C102B8 @default.
- Q37483253 P2860 Q37483253-A6D2D896-8F3E-4A82-99FD-13F3666FE04C @default.
- Q37483253 P2860 Q37483253-B212685B-5466-40FD-98EA-07A4C19BE2A2 @default.
- Q37483253 P2860 Q37483253-B7867B1B-7BEC-48DE-9B73-4B948055DDCC @default.
- Q37483253 P2860 Q37483253-D0168944-B0FC-4ACA-A8E8-4AE61535E830 @default.
- Q37483253 P2860 Q37483253-D38C6D4F-203C-4A1B-8863-4B26A363873E @default.
- Q37483253 P2860 Q37483253-E8478BB3-7672-4F00-A3F1-D59A4EE91BC0 @default.
- Q37483253 P2860 Q37483253-F58578F8-26C8-45C5-BD8B-9B47ED16F11D @default.
- Q37483253 P304 Q37483253-A871BA95-156A-466C-9820-5D1FA921832D @default.
- Q37483253 P31 Q37483253-44129BD1-76BC-467D-A234-2B3CC287E43E @default.
- Q37483253 P356 Q37483253-250A512E-C7FA-4055-9B74-69EC88A92A62 @default.
- Q37483253 P407 Q37483253-FB0763AC-395C-4C32-BEC0-96AD46739727 @default.
- Q37483253 P433 Q37483253-7F1C98A3-9DBC-4C7B-A3BB-54918F7D6442 @default.
- Q37483253 P478 Q37483253-AB1D5837-3993-4ABB-9517-729BDC854F41 @default.
- Q37483253 P50 Q37483253-5482E58E-F7B8-4126-B33B-5F6C0EC3F395 @default.
- Q37483253 P50 Q37483253-573DABE1-7070-49F6-A847-FDC03E851E8A @default.
- Q37483253 P50 Q37483253-6873D01E-16FD-4210-8781-FF841B10E5B3 @default.
- Q37483253 P50 Q37483253-80B9616F-3444-4F85-9954-6D87C8328EE1 @default.
- Q37483253 P50 Q37483253-E5D30302-D22C-4E6E-9F3D-456A13411FB1 @default.
- Q37483253 P577 Q37483253-0647BB90-1E6D-456A-A9A8-0335F6CC7C69 @default.
- Q37483253 P5875 Q37483253-77727951-1D43-409B-AC9E-85B859D0655E @default.
- Q37483253 P698 Q37483253-C57EE7B1-CFF9-43F8-9854-CAD025FAA75A @default.
- Q37483253 P921 Q37483253-A85A37A0-EA43-47D9-B270-3641905FF2E7 @default.
- Q37483253 P921 Q37483253-F329AF21-2886-4574-8190-560A13E50D01 @default.
- Q37483253 P932 Q37483253-9B30591B-4831-4852-945F-475C90BA9F8A @default.
- Q37483253 P356 CNCR.26571 @default.
- Q37483253 P698 22006179 @default.
- Q37483253 P1433 Q326041 @default.
- Q37483253 P1476 "A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer" @default.
- Q37483253 P2093 "Abeena Brewster" @default.
- Q37483253 P2093 "Daniel Booser" @default.
- Q37483253 P2093 "Edgardo Rivera" @default.
- Q37483253 P2093 "Hai T Tran" @default.
- Q37483253 P2093 "James L Murray" @default.
- Q37483253 P2093 "Julia Moore" @default.
- Q37483253 P2093 "Massimo Cristofanilli" @default.
- Q37483253 P2093 "Stacy Moulder" @default.
- Q37483253 P2860 Q29614242 @default.
- Q37483253 P2860 Q30657347 @default.
- Q37483253 P2860 Q33202430 @default.
- Q37483253 P2860 Q33236663 @default.
- Q37483253 P2860 Q33328841 @default.
- Q37483253 P2860 Q33345496 @default.
- Q37483253 P2860 Q33382682 @default.
- Q37483253 P2860 Q34010378 @default.
- Q37483253 P2860 Q34130665 @default.
- Q37483253 P2860 Q34524041 @default.
- Q37483253 P2860 Q35170258 @default.